Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
467 trials
Recruiting nowPhase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Recruiting nowNot phased
Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized Trial
Recruiting nowPhase 2
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Recruiting nowPhase 2
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
Recruiting nowPhase 1
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Recruiting nowPhase 2
Single cEll pRofiling PErsistaNce To ImmuNothErapy
Recruiting nowNot phased
Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer
Recruiting nowPhase 2
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Recruiting nowPhase 1
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Recruiting nowPhase 2
A Study of YL202 in Patients With Advanced Solid Tumors
Recruiting nowPhase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Recruiting nowPhase 2
Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC
Recruiting nowPhase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Recruiting nowPhase 2
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Recruiting nowPhase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors